Abbott Launches Next-Generation Oncodetect Test For Cancer Residual Disease Detection RTT News 15:17 Mon, 26 Oct
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment Abbott Laboratories (Press Release) 13:08 Mon, 26 Oct
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer Abbott Laboratories (Press Release) 14:15 Fri, 23 Oct
Abbott Laboratories vs. Unitedhealth: Does health innovation or health insurance make for a better stock to buy? The Motley Fool 18:37 Sat, 24 Oct UnitedHealth Group Healthcare Pharma All sources
Abbott launches next-generation Oncodetect test for cancer residual disease detection RTT News 15:17 Mon, 26 Oct Oncodetect Pharma Biotech
